查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573069

阻塞性支气管炎症候群市场：依疾病类型、治疗类型、最终用户、药物类型、给药途径、患者特征、诊断方法 - 2025-2030 年全球预测

Bronchiolitis Obliterans Syndrome Market by Disease Type, Treatment Type, End-User, Drug Type, Route of Administration, Patient Demographics, Diagnosis Method - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年阻塞性支气管炎症候群市值为6,753万美元，预估至2024年将达7,325万美元，复合年增长率为8.37%，至2030年将达1,1854万美元。

闭塞性支气管炎症候群 (BOS) 是一种严重的进行性性肺部疾病，通常与肺移植患者的慢性排斥反应有关，导緻小气道闭塞。除了支持性护理和免疫抑制剂之外，管理方法的进展有限，凸显了对 BOS 进行针对性研究和治疗应用的必要性。因此，医院、研究机构和移植中心在最终用途上占据显着地位，凸显了对专门治疗方法和诊断工具的需求。根据市场洞察，肺移植数量的增加和对移植后併发症认识的提高是关键的成长要素。诊断方法的技术进步，例如成像技术和生物标誌物，正在为相关人员创新和利用新技术创造潜在机会。抓住这些机会的建议包括投资下一代治疗和诊断方法的研究和开发，以提供早期检测和个人化治疗策略。然而，市场成长受到临床试验的复杂性和成本、监管障碍以及缺乏有效治疗方法等挑战的阻碍。为了应对这些挑战，生技公司、研究机构和监管机构必须共同努力，简化流程并加速新治疗方法的发现。最具创新潜力的领域包括开发非侵入性诊断工具、精准医学方法和肺组织修復的再生疗法。 BOS 市场的高度专业化和研究主导的性质要求关注临床医生和行业研究人员之间的长期伙伴关係和知识交流。此外，将人工智慧整合到临床决策、患者结果的预测分析以及用于远端监测 BOS 患者的远端医疗平台将有助于克服地理障碍并优化这一利基市场的资源分配，并有可能进一步增加研究。

主要市场统计
基准年[2023] 6753万美元
预测年份 [2024] 7325万美元
预测年份 [2030] 11854万美元
复合年增长率（%） 8.37%

市场动态：快速发展的支气管炎阻塞性综合症市场的关键市场洞察

阻塞性支气管炎综合症市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 医疗技术和治疗的进步可以更好地治疗阻塞性支气管炎综合征
    • 肺部疾病盛行率的增加导致对阻塞性支气管炎症候群治疗的需求增加
    • 增加医疗支出和政府资助以支持阻塞性细支气管炎的研究和开发
    • 提高医疗保健专业人员和患者对阻塞性支气管炎综合征及其治疗方法的认识
  • 市场限制因素
    • 阻塞性支气管炎症候群的研究经费和投资有限正在阻碍进展。
  • 市场机会
    • 治疗阻塞性支气管炎症候群患者的先进治疗方法的出现
    • 扩大阻塞性支气管炎症候群创新治疗方法的研发活动
    • 扩大宣传宣传活动以促进阻塞性支气管炎症候群的早期发现
  • 市场挑战
    • 严格的监管核准流程减缓了阻塞性支气管炎症候群的新治疗方法

波特的五力：驾驭阻塞性支气管炎症候群市场的策略工具

波特的五力架构是了解阻塞性支气管炎症候群市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解支气管炎阻塞性综合症市场的外部影响

外部宏观环境因素在塑造支气管炎阻塞性综合症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解阻塞性支气管炎症候群市场的竞争状况

阻塞性支气管炎综合症市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵阻塞性支气管炎症候群市场供应商的绩效评估

FPNV 定位矩阵是评估阻塞性支气管炎症候群市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了阻塞性支气管炎综合症市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对阻塞性支气管炎综合症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 医疗技术和治疗方法的进步改善了阻塞性支气管炎综合症的治疗
      • 肺部疾病盛行率的增加导致对阻塞性支气管炎症候群治疗方法的需求增加
      • 不断上涨的医疗成本和政府资助推动阻塞性细支气管炎的研究和开发
      • 医疗保健专业人员和患者对阻塞性支气管炎综合征及其治疗方法的认识不断提高
    • 抑制因素
      • 阻塞性支气管炎症候群的研究经费和投资有限阻碍了进展
    • 机会
      • 治疗阻塞性支气管炎症候群患者的新先进治疗方法
      • 扩大阻塞性支气管炎症候群创新治疗方法的研发活动
      • 扩大宣传宣传活动，加强阻塞性支气管炎症候群的早期发现
    • 任务
      • 严格的监管核准程序减缓了阻塞性支气管炎症候群的新治疗方法
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 阻塞性支气管炎症候群市场：依疾病类型

  • 阻塞性支气管炎症候群
  • 阻塞性细支气管炎综合症

第七章阻塞性支气管炎症候群市场：依治疗类型

  • 非药物治疗
    • 氧气疗法
    • 呼吸復健
    • 手术治疗
  • 药物治疗
    • 抗生素
    • 皮质类固醇
    • 免疫抑制剂

第八章阻塞性支气管炎症候群市场：依最终用户

  • 门诊手术中心
  • 家庭护理设置
  • 医院
  • 专科诊所

第九章阻塞性支气管炎症候群市场：依药物类型

  • 品牌
  • 非专利的

第 10 章 阻塞性支气管炎症候群市场：依给药途径

  • 吸入
  • 静脉
  • 口服

第十一章阻塞性支气管炎症候群市场：依病患属性

  • 成人用
  • 老年病
  • 小儿科

第十二章阻塞性支气管炎症候群市场：依诊断方法

  • 验血
  • 高解析度电脑断层扫描
  • 切片检查
  • 肺功能检查

第十三章美洲阻塞性支气管炎症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太地区阻塞性支气管炎症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲/中东/非洲阻塞性支气管炎症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca
  • 4. Boehringer Ingelheim
  • 5. Bristol-Myers Squibb Company
  • 6. Chiesi Farmaceutici SpA
  • 7. Eli Lilly and Company
  • 8. FibroGen, Inc.
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline plc
  • 11. Insmed Incorporated
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Theravance Biopharma
Product Code: MRR-535C62918A91

The Bronchiolitis Obliterans Syndrome Market was valued at USD 67.53 million in 2023, expected to reach USD 73.25 million in 2024, and is projected to grow at a CAGR of 8.37%, to USD 118.54 million by 2030.

Bronchiolitis Obliterans Syndrome (BOS) is a severe, progressive lung condition often associated with chronic rejection in lung transplant patients, leading to obliteration of the small airways. The necessity for targeted research and treatment applications of BOS is underscored by the limited advancements in management approaches beyond supportive care and immunosuppressive drugs. Consequently, the end-use scope prominently features hospitals, research institutions, and transplantation centers, emphasizing the need for specialized therapies and diagnostic tools. Market insights reveal that the rising number of lung transplants and increased awareness of post-transplant complications are significant growth factors. Technological advancements in diagnostic methodologies, such as imaging techniques and biomarkers, are creating potential opportunities for stakeholders to innovate and capitalize on emerging technologies. Recommendations to seize these opportunities include investing in R&D for next-generation therapeutics and diagnostics that can provide early detection and personalized treatment strategies. However, market growth is challenged by limitations such as the complexity and cost of clinical trials, regulatory hurdles, and the scarcity of effective therapeutic options. Addressing these challenges requires collaborative efforts between biotechnology firms, research institutes, and regulatory bodies to streamline processes and encourage novel therapeutic discoveries. Areas offering the best potential for innovation include the development of non-invasive diagnostic tools, precision medicine approaches, and regenerative therapies aimed at lung tissue repair. The nature of the BOS market is highly specialized and research-driven, necessitating a focus on long-term partnerships and knowledge exchange between clinicians and industry researchers. Moreover, the integration of artificial intelligence in clinical decision-making, predictive analytics for patient outcomes, and telemedicine platforms for remote monitoring of BOS patients could further augment research and business growth, overcoming geographical barriers and optimizing resource allocation within this niche market.

KEY MARKET STATISTICS
Base Year [2023] USD 67.53 million
Estimated Year [2024] USD 73.25 million
Forecast Year [2030] USD 118.54 million
CAGR (%) 8.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchiolitis Obliterans Syndrome Market

The Bronchiolitis Obliterans Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in medical technology and treatments leading to better management of bronchiolitis obliterans syndrome
    • Increasing prevalence of lung diseases contributing to higher demand for bronchiolitis obliterans syndrome therapies
    • Rising healthcare expenditure and government funding boosting research and development in bronchiolitis obliterans
    • Growing awareness among healthcare professionals and patients about bronchiolitis obliterans syndrome and its treatments
  • Market Restraints
    • Limited research funding and investment in bronchiolitis obliterans syndrome hindering advancements
  • Market Opportunities
    • Emerging advanced therapeutic approaches to treat bronchiolitis obliterans syndrome patients
    • Growing research and development activities for innovative bronchiolitis obliterans syndrome treatments
    • Expanding public awareness campaigns to enhance early detection of bronchiolitis obliterans syndrome
  • Market Challenges
    • Stringent regulatory approval processes delaying new treatments for bronchiolitis obliterans syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Bronchiolitis Obliterans Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchiolitis Obliterans Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchiolitis Obliterans Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchiolitis Obliterans Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchiolitis Obliterans Syndrome Market

A detailed market share analysis in the Bronchiolitis Obliterans Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchiolitis Obliterans Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchiolitis Obliterans Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchiolitis Obliterans Syndrome Market

A strategic analysis of the Bronchiolitis Obliterans Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiolitis Obliterans Syndrome Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Eli Lilly and Company, FibroGen, Inc., Gilead Sciences, GlaxoSmithKline plc, Insmed Incorporated, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.

Market Segmentation & Coverage

This research report categorizes the Bronchiolitis Obliterans Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Bronchiolitis Obliterans Syndrome and Non-Bronchiolitis Obliterans Syndrome.
  • Based on Treatment Type, market is studied across Non-Pharmacological Treatment and Pharmacological Treatment. The Non-Pharmacological Treatment is further studied across Oxygen Therapy, Pulmonary Rehabilitation, and Surgical Therapy. The Pharmacological Treatment is further studied across Antibiotics, Corticosteroids, and Immunosuppressive Agents.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Drug Type, market is studied across Branded and Generic.
  • Based on Route of Administration, market is studied across Inhalation, Intravenous, and Oral.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Diagnosis Method, market is studied across Blood Tests, High-Resolution CT Scan, Lung Biopsy, and Pulmonary Function Tests.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in medical technology and treatments leading to better management of bronchiolitis obliterans syndrome
      • 5.1.1.2. Increasing prevalence of lung diseases contributing to higher demand for bronchiolitis obliterans syndrome therapies
      • 5.1.1.3. Rising healthcare expenditure and government funding boosting research and development in bronchiolitis obliterans
      • 5.1.1.4. Growing awareness among healthcare professionals and patients about bronchiolitis obliterans syndrome and its treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited research funding and investment in bronchiolitis obliterans syndrome hindering advancements
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging advanced therapeutic approaches to treat bronchiolitis obliterans syndrome patients
      • 5.1.3.2. Growing research and development activities for innovative bronchiolitis obliterans syndrome treatments
      • 5.1.3.3. Expanding public awareness campaigns to enhance early detection of bronchiolitis obliterans syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory approval processes delaying new treatments for bronchiolitis obliterans syndrome
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchiolitis Obliterans Syndrome Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Bronchiolitis Obliterans Syndrome
  • 6.3. Non-Bronchiolitis Obliterans Syndrome

7. Bronchiolitis Obliterans Syndrome Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Non-Pharmacological Treatment
    • 7.2.1. Oxygen Therapy
    • 7.2.2. Pulmonary Rehabilitation
    • 7.2.3. Surgical Therapy
  • 7.3. Pharmacological Treatment
    • 7.3.1. Antibiotics
    • 7.3.2. Corticosteroids
    • 7.3.3. Immunosuppressive Agents

8. Bronchiolitis Obliterans Syndrome Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Homecare Settings
  • 8.4. Hospitals
  • 8.5. Specialty Clinics

9. Bronchiolitis Obliterans Syndrome Market, by Drug Type

  • 9.1. Introduction
  • 9.2. Branded
  • 9.3. Generic

10. Bronchiolitis Obliterans Syndrome Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Inhalation
  • 10.3. Intravenous
  • 10.4. Oral

11. Bronchiolitis Obliterans Syndrome Market, by Patient Demographics

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Bronchiolitis Obliterans Syndrome Market, by Diagnosis Method

  • 12.1. Introduction
  • 12.2. Blood Tests
  • 12.3. High-Resolution CT Scan
  • 12.4. Lung Biopsy
  • 12.5. Pulmonary Function Tests

13. Americas Bronchiolitis Obliterans Syndrome Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bronchiolitis Obliterans Syndrome Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bronchiolitis Obliterans Syndrome Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca
  • 4. Boehringer Ingelheim
  • 5. Bristol-Myers Squibb Company
  • 6. Chiesi Farmaceutici S.p.A.
  • 7. Eli Lilly and Company
  • 8. FibroGen, Inc.
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline plc
  • 11. Insmed Incorporated
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Theravance Biopharma

LIST OF FIGURES

  • FIGURE 1. BRONCHIOLITIS OBLITERANS SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. BRONCHIOLITIS OBLITERANS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIOLITIS OBLITERANS SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHIOLITIS OBLITERANS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-BRONCHIOLITIS OBLITERANS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SURGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HIGH-RESOLUTION CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SI